Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses

Objectives To characterise the association between type 2 diabetes mellitus (T2DM) subtypes (new-onset T2DM (NODM) or long-standing T2DM (LSDM)) and pancreatic cancer (PC) risk, to explore the direction of causation through Mendelian randomisation (MR) analysis and to assess the mediation role of body mass index (BMI). Design Information about T2DM and related factors was collected from 2018 PC cases and 1540 controls from the PanGenEU (European Study into Digestive Illnesses and Genetics) study. A subset of PC cases and controls had glycated haemoglobin, C-peptide and genotype data. Multivariate logistic regression models were applied to derive ORs and 95% CIs. T2DM and PC-related single nucleotide polymorphism (SNP) were used as instrumental variables (IVs) in bidirectional MR analysis to test for two-way causal associations between PC, NODM and LSDM. Indirect and direct effects of the BMI-T2DM-PC association were further explored using mediation analysis. Results T2DM was associated with an increased PC risk when compared with non-T2DM (OR=2.50; 95% CI: 2.05 to 3.05), the risk being greater for NODM (OR=6.39; 95% CI: 4.18 to 9.78) and insulin users (OR=3.69; 95% CI: 2.80 to 4.86). The causal association between T2DM (57-SNP IV) and PC was not statistically significant (ORLSDM=1.08, 95% CI: 0.86 to 1.29, ORNODM=1.06, 95% CI: 0.95 to 1.17). In contrast, there was a causal association between PC (40-SNP IV) and NODM (OR=2.85; 95% CI: 2.04 to 3.98), although genetic pleiotropy was present (MR-Egger: p value=0.03). Potential mediating effects of BMI (125-SNPs as IV), particularly in terms of weight loss, were evidenced on the NODM-PC association (indirect effect for BMI in previous years=0.55). Conclusion Findings of this study do not support a causal effect of LSDM on PC, but suggest that PC causes NODM. The interplay between obesity, PC and T2DM is complex.

[1]  James D. Johnson,et al.  Endogenous Hyperinsulinemia Contributes to Pancreatic Cancer Development. , 2019, Cell metabolism.

[2]  Kenneth A. Philbrick,et al.  Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma. , 2019, Gastroenterology.

[3]  James D. Johnson,et al.  Endogenous insulin contributes to pancreatic cancer development , 2019, bioRxiv.

[4]  Helen E. Parkinson,et al.  The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 , 2018, Nucleic Acids Res..

[5]  C. Haiman,et al.  Pancreatic Cancer Following Incident Diabetes in African Americans and Latinos: The Multiethnic Cohort , 2018, Journal of the National Cancer Institute.

[6]  T. Smyrk,et al.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. , 2018, Gastroenterology.

[7]  Albert C. Koong,et al.  Altered exocrine function can drive adipose wasting in early pancreatic cancer , 2018, Nature.

[8]  Valeriia Haberland,et al.  The MR-Base platform supports systematic causal inference across the human phenome , 2018, eLife.

[9]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[10]  D. Saur,et al.  Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells. , 2018, Cancer letters.

[11]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[12]  Jessica M B Rees,et al.  Extending the MR‐Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy , 2017, Statistics in medicine.

[13]  S. Thompson,et al.  Interpreting findings from Mendelian randomization using the MR-Egger method , 2017, European Journal of Epidemiology.

[14]  P. Brennan,et al.  The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study , 2017, Journal of the National Cancer Institute.

[15]  Olena O Yavorska,et al.  MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data , 2017, International journal of epidemiology.

[16]  A. Rustgi,et al.  A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. , 2017, Gastroenterology.

[17]  Zhengming Chen,et al.  Diabetes, plasma glucose and incidence of pancreatic cancer: A prospective study of 0.5 million Chinese adults and a meta‐analysis of 22 cohort studies , 2017, International journal of cancer.

[18]  J. Ferlay,et al.  More deaths from pancreatic cancer than breast cancer in the EU by 2017 , 2016, Acta oncologica.

[19]  C. D. De Block,et al.  Diabetes mellitus and pre-diabetes are frequently undiagnosed and underreported in patients referred for pancreatic surgery. A prospective observational study. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[20]  Stephen Burgess,et al.  PhenoScanner: a database of human genotype–phenotype associations , 2016, Bioinform..

[21]  Iain Buchan,et al.  Collider Bias Is Only a Partial Explanation for the Obesity Paradox , 2016, Epidemiology.

[22]  G. Davey Smith,et al.  Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator , 2016, Genetic epidemiology.

[23]  T. VanderWeele Mediation Analysis: A Practitioner's Guide. , 2016, Annual review of public health.

[24]  G. Davey Smith,et al.  Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies1 , 2016, The American journal of clinical nutrition.

[25]  J. Connett,et al.  Role of survivor bias in pancreatic cancer case-control studies. , 2016, Annals of epidemiology.

[26]  N. Malats,et al.  Reduced risk of pancreatic cancer associated with asthma and nasal allergies , 2015, Gut.

[27]  Benjamin S. Glicksberg,et al.  Identification of type 2 diabetes subgroups through topological analysis of patient similarity , 2015, Science Translational Medicine.

[28]  Bao-sheng Wang,et al.  Long-Term Diabetes Mellitus Is Associated with an Increased Risk of Pancreatic Cancer: A Meta-Analysis , 2015, PloS one.

[29]  L. Levin,et al.  Biodiversity on the Rocks: Macrofauna Inhabiting Authigenic Carbonate at Costa Rica Methane Seeps , 2015, PloS one.

[30]  G. Petersen,et al.  Do Variants Associated with Susceptibility to Pancreatic Cancer and Type 2 Diabetes Reciprocally Affect Risk? , 2015, PloS one.

[31]  P. Maisonneuve,et al.  Risk factors for pancreatic cancer: a summary review of meta-analytical studies. , 2015, International journal of epidemiology.

[32]  S. Thompson,et al.  Multivariable Mendelian Randomization: The Use of Pleiotropic Genetic Variants to Estimate Causal Effects , 2015, American journal of epidemiology.

[33]  Heng-Yi Wu,et al.  Extraction of Pharmacokinetic Evidence of Drug–Drug Interactions from the Literature , 2014, PloS one.

[34]  A. Butterworth,et al.  Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways , 2014, International journal of epidemiology.

[35]  G. Honda,et al.  Case-control study of diabetes-related genetic variants and pancreatic cancer risk in Japan. , 2014, World journal of gastroenterology.

[36]  Zheng Wang,et al.  Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. , 2014, Diabetes research and clinical practice.

[37]  A. Miller,et al.  Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  M. Reni,et al.  Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients , 2014, Acta Diabetologica.

[39]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[40]  S. Vander Hoorn,et al.  Association of Diabetes Mellitus and Pancreatic Adenocarcinoma: A Meta-Analysis of 88 Studies , 2014, Annals of surgical oncology.

[41]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[42]  E. Riboli,et al.  Genes–Environment Interactions in Obesity- and Diabetes-Associated Pancreatic Cancer: A GWAS Data Analysis , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[43]  A. Butterworth,et al.  Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data , 2013, Genetic epidemiology.

[44]  P. Vigneri,et al.  Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[45]  Suresh T. Chari,et al.  New insights into pancreatic cancer-induced paraneoplastic diabetes , 2013, Nature Reviews Gastroenterology &Hepatology.

[46]  Charles E McCulloch,et al.  Estimation of covariate effects in generalized linear mixed models with a misspecified distribution of random intercepts and slopes , 2013, Statistics in medicine.

[47]  S. Chari,et al.  Prevalence of Diabetes Mellitus in Pancreatic Cancer Compared to Common Cancers , 2013, Pancreas.

[48]  N. Sasahira,et al.  Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age , 2013, Journal of Gastroenterology.

[49]  E. Riboli,et al.  Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort , 2011, Diabetologia.

[50]  Jun Liu,et al.  Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. , 2011, European journal of cancer.

[51]  Ananda Basu,et al.  Weight Loss Precedes Cancer-Specific Symptoms in Pancreatic Cancer-Associated Diabetes Mellitus , 2011, Pancreas.

[52]  B. Pierce,et al.  Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data , 2011, Cancer Causes & Control.

[53]  Manal M. Hassan,et al.  Body Mass Index and Obesity- and Diabetes-Associated Genotypes and Risk for Pancreatic Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[54]  M. Tobin,et al.  Mendelian Randomisation and Causal Inference in Observational Epidemiology , 2008, PLoS medicine.

[55]  Mariza de Andrade,et al.  Probability of pancreatic cancer following diabetes: a population-based study. , 2005, Gastroenterology.

[56]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.